Request Demo
Recent blog posts
Latest Hotspot
8 min read
Hairy cell leukemia variant Indication Strategy Report 2026: BRAF, Trials and Deals
30 July 2026
2026 Hairy cell leukemia variant indication strategy covering epidemiology, BRAF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Subcutaneous panniculitis-like T-cell lymphoma Indication Strategy Report 2026: HAVCR2, Trials and Deals
30 July 2026
2026 Subcutaneous panniculitis-like T-cell lymphoma indication strategy covering epidemiology, HAVCR2 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
B-cell prolymphocytic leukemia Indication Strategy Report 2026: BCL2, Trials and Deals
30 July 2026
2026 B-cell prolymphocytic leukemia indication strategy covering epidemiology, BCL2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
T-cell prolymphocytic leukemia Indication Strategy Report 2026: TCL1A, Trials and Deals
30 July 2026
2026 T-cell prolymphocytic leukemia indication strategy covering epidemiology, TCL1A biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Primary cutaneous gamma delta T-cell lymphoma Indication Strategy Report 2026: JAK1, Trials and Deals
30 July 2026
2026 Primary cutaneous gamma delta T-cell lymphoma indication strategy covering epidemiology, JAK1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Intraocular lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
30 July 2026
2026 Intraocular lymphoma indication strategy covering epidemiology, BTK biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Primary vitreoretinal lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
30 July 2026
2026 Primary vitreoretinal lymphoma indication strategy covering epidemiology, BTK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Testicular lymphoma Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Testicular lymphoma indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Fumarate hydratase-deficient renal cell carcinoma Indication Strategy Report 2026: HIF2A, Trials and Deals
30 July 2026
2026 Fumarate hydratase-deficient renal cell carcinoma indication strategy covering epidemiology, HIF2A biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
MiT family translocation renal cell carcinoma Indication Strategy Report 2026: TFE3, Trials and Deals
30 July 2026
2026 MiT family translocation renal cell carcinoma indication strategy covering epidemiology, TFE3 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Oncocytic renal neoplasm Indication Strategy Report 2026: mTOR, Trials and Deals
30 July 2026
2026 Oncocytic renal neoplasm indication strategy covering epidemiology, mTOR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Collecting duct carcinoma Indication Strategy Report 2026: MET, Trials and Deals
30 July 2026
2026 Collecting duct carcinoma indication strategy covering epidemiology, MET biology, active trials, transactions, unmet need, competition and market…